prospective study to evaluate patient reported outcomes (pro) during rechallenge with trabectedin in sarcoma patients

Conditions: Soft Tissue Sarcoma

Summary: chemotherapy with trabectedin is an effective treatment for sarcoma patients in the second line setting or in first line for patients who are deemed unsuitable to receive anthracycline therapy. the prospective study will primarily investigate the pro of trabectedin rechallenge in patients with soft tissue sarcomas that had to discontinue initial trabectedin treatment due to various reasons such as progression, side effects or surgery, as is commonly the case in real-life settings. embedding this trial in the gisar registry enables the evaluation of a large number of patients with long-term follow-up which allows multiple analyses regarding different questions that remain unanswered until today.

chemotherapy with trabectedin is an effective treatment for sarcoma patients in the second line setting or in first line for patients who are deemed unsuitable to receive anthracycline therapy. several features differentiate its clinical performance from other chemotherapeutic agents, including durability of response and the absence of cumulative toxicity even upon re-exposition to treatment after interruption of therapy. in addition, the results of the t-dis trial evaluating the impact of trabectedin rechallenge demonstrated that it retains its activity when patients are rechallenged on progression after a treatment break. since sarcoma patient usually report a worse global quality of life (qol) compared to the general population, one of the main goals of treating advanced-stage patients with trabectedin, in addition to its efficacy, is to improve the qol, represented by symptom control and other patient-related outcomes. however, little is known to date about the qol during a rechallenge with trabectedin, after patients had to discontinue trabectedin treatment. patient-reported outcome (pro) measures are standardized questionnaires that collect information on health outcomes directly from the patients, including symptoms, health-related qol parameters and functional status. in general, there are two types of proms, disease-specific and general measures that can also be used for healthy populations. a growing number of articles supports the need for, as well as the benefit of, deriving information directly from patients. thus, the application of pro measures, initially developed for the use in research, has become more common nowadays and their application is included in supporting clinical decision making, comparing outcomes among health-care providers, stimulating quality improvement and evaluating practices and policies. therefore, the collection of real-world data from patients subject to trabectedin rechallenge would enable further estimations on the feasibility and efficacy of trabectedin rechallenge. the prospective protrasarc sub-study will primarily investigate the pro of trabectedin rechallenge in patients with soft tissue sarcomas that had to discontinue initial trabectedin treatment due to various reasons such as progression, side effects or surgery, as is commonly the case in real-life settings. embedding this trial in the gisar registry enables the evaluation of a large number of patients with long-term follow-up which allows multiple analyses regarding different questions that remain unanswered until today.

Eligibility criteria:
inclusion criteria: * enrolled participant of the gisar registry and their sub-studies * patient with histologically confirmed soft tissue sarcomas * pretreatment with trabectedin, termination of this therapy regardless of reason * planned rechallenge or started rechallenge with trabectedin in any line of therapy within 2 weeks before inclusion * interval between last trabectedin treatment and trabectedin rechallenge at least 3 months exclusion criteria: * not able to understand all implications of study participation * no written informed consent * age ≤ 18 years

Keywords: re-challenge trabectedin sarcoma registry pro